Editas Q3 net loss widens to $62.1M; cash runway extended into Q2 2026

Editas Medicine, Inc.

2024-Q3 EPS reported -$2.33 revenue$1,710,000

Q3 2024 net loss of $62.1M ($0.75/sh) vs $45.0M ($0.55/sh) in Q3 2023; R&D spend up $7.1M.
Cash, equivalents and securities $265.1M at Sept 30; with DRI $57M upfront totals ~$322.1M.
In vivo preclinical proof of concept for HBG1/2 editing in HSPCs using targeted LNP achieved.
Reni-cel partnering process with Moelis & Co underway; 28-patient RUBY update at ASH in December.
Collaboration revenue fell to $0.1M from $5.3M on prior-year Vor Bio upfront payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.